Chapter 16: Growth Factor & Cytokine Signaling

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome back to the Deep Dive.

Our mission today is, well, it's pretty foundational.

We're going to be looking at how cells translate this complex language of communication into real lasting change.

Exactly.

We're plunging into the major extracellular signaling pathways.

And the key thing here is that they don't just prompt a quick reaction.

They fundamentally rewrite the cell's future by regulating gene expression.

And that's the crucial distinction for this whole dive, isn't it?

It's the difference between short -term and long -term effects.

It really is.

I mean, if a cell needs an instant short -term effect, like, say, tweaking an enzyme's activity, it can just modify a protein that's already there.

That's one kind of signaling, quick and dirty.

But when the cell needs to commit to something big, a long -term fate dividing, specializing into a new tissue, mounting a full -blown immune response, it has to change the expression of, you know, potentially hundreds of different genes.

And that's where these signals, hormones, growth factors, they're the ultimate puppet masters.

They absolutely are.

And because these pathways are so central to a cell's destiny, when the machinery breaks down, the consequences are, well, they're catastrophic.

That's putting it mildly.

I mean, you can't really discuss cancer or diabetes or serious immune disorders without digging into how these specific signaling systems have been hijacked or broken.

So to really set the stage for how powerful these pathways are, let's go back to that startling image you mentioned before, the planarian flatworm.

Ah, yes.

The worm that regenerates multiple heads.

That's such a potent visual.

It is, because it shows you the absolute power of this genetic switch.

A planarian is an expert regenerator, but that process has to be so tightly controlled.

There's a pathway, the Wnt signaling pathway, which is incredibly conserved across evolution, that normally tells the worm to regenerate a tail.

And crucially, it inhibits head formation.

Exactly.

It says tail here, not head.

So if you just turn off that Wnt signal, what happens?

Well, researchers did exactly that.

They inhibited a single protein in the Wnt pathway, beta -catenin 1.

And when they did that, the natural repair mechanisms at every single wound site, they just defaulted to making a head.

So you end up with this monstrosity with heads sprouting out all over the place.

You do.

And that one experiment just demonstrates the profound, almost scary power these pathways have over basic cell fate and body patterning.

That's a perfect hook.

These signals literally determine if you grow a head or a tail.

Okay, so let's untack this systemically.

Before we get into the specific cascades, what are the common themes here?

What are the ground rules for all these different pathways?

There are three critical recurring ideas.

First, the key switches, the transcription factors or TFs that actually bind the DNA, are almost always kept inactive and parked out in the cytosol.

They're waiting outside the control room essentially.

Exactly.

So when the pathway gets activated, the signal does one of two things to that transcription factor.

It either physically triggers its transport into the nucleus.

Like give you the ticket to get in.

Right, by unmasking a hidden nuclear localization sequence, an NLS.

Or it activates the factor right where it is, through phosphorylation, which then allows it to bind DNA.

Okay, that's one.

What's the second thing?

The sheer age of these systems?

The conservation is just staggering.

We see the same handful of receptor classes and pathways everywhere.

From worms to us.

From worms to us.

When scientists first discovered the hedgehog pathway, it was in fruit fly mutants.

We now know the same basic components regulate everything from how our neural tube patterns to how a mouse's limbs develop.

And the third theme has to be the breaks.

Because if these signals are so powerful, you absolutely need a way to turn them off.

That is the third crucial point, negative feedback.

Because these changes are so profound, the cell has to regulate itself.

So a transcription factor, once it gets into the nucleus and does its job, very often turns on the synthesis of proteins, whose only job is to go back and shut down the very pathway that activated them.

It's a built -in off switch to prevent overstimulation.

So we're looking at a tightly regulated, ancient system of switches, transport, and self -destruct breaks.

Let's start with maybe the most famous mechanism.

Receptor tyrosine kinases,

or RTKs.

Yes.

These are the cell's main receivables for growth and survival factors.

They pick up signals from a huge class of hormones and proteins.

Things like nerve growth factor, platelet -derived growth factor, EGF.

And also critical stuff like insulin.

Right.

And, you know, the name itself tells you what it does.

They are kinases that phosphorylate tyrosine residues.

And a lot of these were first discovered in cancer research, right?

They were, because mutant forms of these receptors can get stuck in the on -end position.

They become what we call constitutively active, where the kinase is just firing all the time, even with no signal driving uncontrolled cell growth.

So structurally, what does a single RTK protein look like?

Okay.

So picture a protein that crosses the membrane just one time.

It's got a big domain on the outside that binds the ligand.

A single alpha helix that goes through the membrane.

And then on the inside, in the cytosol, you have the domain, the tyrosine kinase activity.

And a C -terminal tail that's full of tyrosines just waiting to be phosphorylated.

And in the resting state, these are just floating around as single units, inactive.

How does the signal turn them on?

The whole mechanism is based on one simple idea.

Proximity.

Specifically, dimerization.

They have to team up.

They have to team up.

In the resting state, the kinase activity is really poor because a part of the protein called the activation loop physically blocks the catalytic site.

But when the ligand binds on the outside, it physically forces two of these monomeric receptors to come together into a dimer.

And bringing them together brings those kinase domains close enough to do their thing, which is?

Transphosphorylation.

The weakly active kinase in one subunit is now perfectly positioned to reach over and phosphorylate a key tyrosine on the activation loop of the other subunit.

Ah, so they activate each other.

They activate each other.

And that phosphorylation causes a big conformational change.

The activation swings out of the way, the catalytic site opens up, and the kinase activity just skyrockets.

The switch is flipped.

That is so elegant.

The simple act of binding the signal creates the active enzyme.

So what happens once that kinase is fully powered up?

It gets to work.

It starts phosphorylating a bunch of other tyrosine residues all over its own C terminal tail.

And this is the whole point.

These new phosphotyrosines, they aren't just chemical tags.

They are specialized docking sites.

Landing pads.

Perfect analogy.

They're temporary specific landing pads for all the downstream signaling proteins to come and bind to.

Now, I find it fascinating that this dimerization mechanism isn't always the same.

Can you give us an example of a variation?

Sure.

Take this fibroblast growth factor, or FGF receptor.

In that case, two FGF ligands bind at the same time to both receptor subunits, really locking the dimer together.

And what's even cooler is that the extracellular matrix gets involved.

There's a polysaccharide in the matrix called heparin sulfate.

It actually binds to both the ligand and the receptor, acting like a kind of molecular glue to hold everything in the perfect arrangement for signaling.

It shows that even the cell's environment is part of the conversation.

Well, so the matrix itself is a cofactor.

What about the insulin receptor?

That one's a bit of an outlier, right?

It is.

It actually exists as a preformed dimer held together by disulfide bonds, even before insulin shows up.

So for the insulin receptor, insulin binding doesn't cause dimerization.

It causes a shape change in the dimer that's already there.

Exactly.

The external part of the receptor shifts from an inverted U shape to a T shape, and that movement is just enough to push the internal kinase domains close enough to transphosphorylate and activate.

Okay, so that tail is now decorated with all these phosphotyrosine docking sites.

This brings us to these specialized binding domains.

How does a protein know which phosphotyrosine to bind to?

That is the genius of the SH2 domain.

It stands for SESRC -Homology -2.

These are highly conserved protein modules that are designed to bind phosphotyrosine.

But not just any phosphotyrosine.

Not just any, and this is the key.

The SH2 domain recognizes the phosphotyrosine, plus a few specific amino acid residues right next to it.

So it's like a two -prong plug.

Yeah.

One prong is the phosphate group, which is the same everywhere, but the other prong has to fit the specific amino acid side chains next to it.

Precisely.

For example, the SH2 domain of a kinase called Secture WSI binds really strongly to the sequence PYEI, that's phosphotyrosine, followed by two glutamic acids and an isoleucine.

That dual recognition ensures it only docks at the right place.

And we should also mention their partners, the SH3 domains.

Absolutely.

SH3 domains are just as critical.

They don't bind phosphotyrosine, they bind to specific proline -rich sequences and other proteins.

Together, SH2 and SH3 domains are like the Lego bricks that the cell uses to build these complex signaling machines right at the membrane.

Let's look at a real -world example, the HERA -GF receptor family.

This is so important in cancer biology.

It is.

So you have four members, HER1 through HF4.

HER1 is the classic model,

a ligand -like EGF binds that exposes a dimerization arm, and it pairs up with another HR1.

Simple.

But the family has some interesting quirks, especially H2.

Right.

HER2 is clinically the most important one.

It's unique because it can't bind any ligand at all.

But its dimerization arm is always exposed.

It's always ready to partner up.

So it's like a universal adapter.

It is.

It readily forms these highly active heterodimers with any other hair family member that is bound to ligand.

So it ends up amplifying the signal for the entire family.

And then you have H3 on the other end of the spectrum.

The weak partner.

HR3 can bind a ligand, but its kinase domain is basically dead.

It can only signal effectively when it pairs up with HR2, which provides the kinase power for the team.

This family also has a slightly different way of activating its kinase, doesn't it?

It's not just about the activation loop.

That's right.

The EGF receptor relies on forming an asymmetric kinase dimer inside the cell.

It's really elegant.

The C -lobe of one kinase, the donor, physically pushes against the N -lobe of the other kinase, the acceptor.

And that physical push is what activates it.

That push is what mechanically displaces the acceptor's activation loop and gets the signal started.

The phosphorylation of the loop happens a moment later to lock it into a fully active state.

And this brings us right back to cancer.

The overproduction of HR2.

If a cell has too many copies of the HR2 gene, which happens in about a quarter of breast cancers, the cell becomes hypersensitive.

With so many ready -to -go HR2 partners available, even tiny ambient amounts of growth factors can trigger massive inappropriate cell growth.

Okay, so we know how to turn the signal on.

How does the cell turn it off?

What are the breaks for RTKs?

Two levels of control.

There's a fast molecular mechanism and then a slower, more permanent one.

The fast one involves phosphotyrosine phosphatases.

These are enzymes that are constantly working to clip the phosphates off of those tyrosine residues.

So they're always cleaning up the signal.

Constantly cleaning.

And the second, more permanent shutdown, that's receptor -mediated endocytosis.

If the receptor is stimulated for too long, the cell starts to internalize it.

It pulls it in from the membrane.

And there's a specific destroy -me tag involved, right?

Yes.

An E3 ubiquitin ligus called CCBL binds to the phosphorylated receptor.

And critically, it adds a single ubiquitin molecule monobiquitin.

This tag doesn't send it to the proteasome for degradation.

Instead, it acts as a sorting signal that directs the receptor to the lysosome for complete destruction.

An irreversible disposal.

That's a great transition.

We've activated the RTK.

It's created docking sites.

Now, let's follow one of the most important signals downstream.

The RasMap kinase pathway.

Ah, yes.

The universal relay switch for growth.

Pretty much all RTKs feed into this.

It's conserved all the way from yeast to humans.

And it controls these major long -term changes in cell fate.

At the core is Ras, this monomeric GTPase switch protein.

Right.

And Ras works like all G proteins.

On N when it's bound to GTP, OFF when it's bound to GDP.

But Ras itself is actually really slow at turning itself off.

It can't hydrolyze GTP very fast on its own.

Which would make it a pretty bad switch.

A terrible switch.

It would get stuck on N, so it needs help from a partner protein.

The break.

The break.

A GTPase activating protein, or GIP.

RasGAPI comes in and speeds up that hydrolysis by hundreds of times, forcing Ras back into the OFF state.

And that's the exact point of failure in so many cancers.

That is the molecular smoking gun.

The famous glycine -12 mutation in Ras physically blocks the GAP from binding.

So the break can't engage.

And Ras is permanently locked in the active GTP -bound stage, just screaming grow, grow, grow.

OK.

Let's rewind to activation.

The RTK is on.

And it needs to flip Ras from OFF to on N.

But the RTK itself isn't a GEF.

It can't do the nucleoside exchange.

Right.

It uses a brilliant two -part adapter system.

The proteins GRB2 and SOs.

OK.

What do they do?

So first, GRB2, which has an SH2 domain, docks onto the phosphorylated RTK.

GRB2 is just an adapter, no enzyme activity.

It's the bridge.

It's the bridge.

Because GRB2 also has two SH3 domains.

And these bind to a protein called SOs.

And SOs is the actual guanine nucleotide exchange factor, the GEF, for Ras.

The RTK recruits GRB2.

GRD2 grabs SOs from the cytosol and brings it to the membrane right next to its target, Ras.

Precisely.

Once SOs is there, it engages with the inactive Ras GDP, pries the GDP out.

And since GDP is so abundant in the cell, a new GDP molecule just pops right in.

And now you have active Ras GDP.

Activation complete.

Now, Ras GDP kicks off this three -tiered kinase cascade.

What's the first kinase?

The first kinase is RAF.

This is the classic highly conserved sequence.

RAF phosphorylates MEK and MEK phosphorylates MPEG kinase.

How is RAF kept quiet before the signal arrives?

In a resting cell, RAF is held captive in the cytosol by an inhibitor protein called 1433.

You can think of it as a molecular handcuff, keeping RAF folded up and inactive.

And active Ras is the key that unlocks the handcuffs.

Exactly.

Active Ras GTT binds to RAF, and that binding forces 1433 to let go.

This frees up RAF's active site, allowing it to activate and continue the signal.

So active RAF, a serinithrinine kinase, then activates the second step, MEK.

Right.

RAF phosphorylates and activates MEK.

Now, MEK is interesting.

It's a dual specificity kinase, meaning it can phosphorylate both tyrosine and serinithrinine residues on its substrates.

And finally, MEK activates the last kinase in the chain, MAP kinase.

Yes, and this is where that dual specificity comes in.

To activate MAP kinase, or MAP, MEK has to phosphorylate it on both a threonine and a tyrosine residue in its activation loop.

That double phosphorylation is the final go -ahead.

Active MAPK then dimerizes and heads for the nucleus.

And once it gets into that genetic control room, what does it do?

It's a master regulator.

It's known to phosphorylate over 200 different proteins, a lot of them transcription factors.

Its main job after a growth signal is to turn on what we call early response genes.

Like C -phos.

Like C -phos, which is critical for getting the cell cycle started.

It does this by phosphorylating two transcription factors, TCF and SRF, which then bind to the C -phos promoter and switch on transcription.

And again, we come back to the breaks.

How do you stop this powerful cascade?

You need multiple checks.

For one, the activated MAPK itself can actually turn around and phosphorylate upstream components like RAF at inhibitory sites.

It's a quick self -limiting feedback.

And the longer term shut down.

The signal programs its own destruction.

Active MAPK turns on the transcription of genes that encode for dual specificity phosphatases, or DUSPs.

And as the name suggests, these DUSPs are enzymes that remove both the threonine and the tyrosine phosphates from MPK, shutting it down completely.

Now, you mentioned that these components like MEK and MEK are used in lots of different pathways.

How does a cell keep the signal straight?

How does a yeast cell say not confuse a mating signal with a stress signal?

That is the absolutely critical job of scaffold proteins.

They're like molecular cruise directors.

I like that.

In yeast, the same initial kinase is shared by two pathways.

The ST5 scaffold physically grabs all the components of the mating pathway and holds them together, preventing them from accidentally talking to the stress pathway proteins.

And the stress pathway has its own separate scaffold.

It does.

It keeps the conversation separate and also makes the signaling much more efficient by keeping the enzyme and its substrate right next to each other.

That is such an elegant solution.

OK, let's pivot a little.

We've talked about protein phosphorylation.

Let's look at how signals can be sent using membrane lipids.

The phosphonosetide pathways.

Right.

So activated RTKs can also kick off pathways that use phosphorylated derivatives of a membrane lipid, phosphatidylinesatol.

Let's quickly touch on PLC gamma.

Sure.

Phospholipase C gamma is activated by RTKs.

And unlike the beta version we see with GPCRs, PLC gamma has an SH2 domain.

That SH2 domain lets it dock directly onto the activated RTK, which brings it to the membrane right next to its substrate, PIP2.

Which it then cleaves to generate DAG and IP3, leading to calcium release and PKC activation.

But the really big pathway for long -term survival signals involves PI3 kinase.

Yes.

Phosphatidylinesatol -3 kinase, or PI3 kinase, is also recruited to the activated RTK via its SH2 domain.

And its job is to add a phosphate group to the 3 -carbon of the inocicle ring of these lipids.

Creating a brand new kind of docking site.

Exactly.

It generates these PI3 phosphates.

And these serve as membrane -bound landing pads for proteins that contain a specific binding module called a pH domain.

And the most important protein with a pH domain here is protein kinase B, or PKB, also known as ACT.

PKB is an absolutely essential kinase for cell survival and metabolism.

In a resting cell, it's just floating in the cytosol.

And its own TH domain is actually folded over, blocking its active site.

It's auto -inhibited.

So activation is a two -step process.

First recruitment, then full activation.

Right.

When PI3 kinase creates those docking sites, PKB's pH domain binds to them.

That pulls PKB to the membrane and also causes a conformational change that partially opens up its active site.

And what's the final step to turn it fully on?

It needs to be phosphorylated by two other kinases.

One called PDK1, which is also recruited to the membrane by its pH domain.

And another kinase that's part of the MTORC2 complex.

Once PKB is phosphorylated by both of those, it is fully active.

And its main job is to prevent cell suicide or apoptosis.

How does it do that?

It does it in two major ways.

First, it can directly phosphorylate and inactivate pro -apoptotic proteins, like a protein called BAD.

But it also controls gene expression.

How is so?

It targets a transcription factor called F -OCXO3A.

Normally, F -OCXO3A goes into the nucleus and turns on genes that cause apoptosis.

But active PKB phosphorylates F -OCXO3A.

And that phosphorylation creates a binding site.

The very same.

1433 grabs the phosphorylated F -OCXO3A and just holds it hostage in the cytoplasm, preventing it from ever getting into the nucleus to do its deadly work.

That's a perfect survival mechanism.

So what's the break on this pathway?

We mentioned PTN.

PTN phosphatase is the critical off switch.

It's a tumor suppressor.

Its job is the exact opposite of PI3 kinase.

It removes that 3 -phosphate from the lipids, erasing the docking sites and shutting the whole pathway down.

And if you lose PTN?

You lose PTNA and you lose the break.

And that's one of the most common events in human cancer.

The cell has chronically high levels of PKB activity and becomes almost impossible to kill because its anti -apoptosis programs are always on.

Okay, let's shift gears.

We focused on RTKs that have their own kinase domains.

But other signals, like those for the immune system, use receptors that have to, well, outsource the phosphorylation.

Let's talk about cytokines and the JAKSTAT pathway.

Cytokines are small, secreted proteins that mainly regulate the formation of blood cells,

hematopoiesis, and immune function.

Things like growth hormone, prolactin, or erythropoietin, EPO.

EPO is a great example of this feedback loop.

It's a beautiful system.

Kidney cells sense low oxygen.

They secrete EPO.

EPO travels to the bone marrow and tells red blood cell progenitors to stop dying and instead to proliferate and differentiate like crazy.

And the cytokine receptors, how are they different from RTKs?

Structurally, they're similar, but they have no intrinsic kinase activity.

Instead, their cytosolic domains are permanently attached to a separate family of tyrosine kinases called JAKO kinases.

So the receptor's only job is to bring the JAKES together.

That's it.

The cytokine binds, the receptors dimerize, and that brings the two associated JAKO kinases close enough to transphosphorylate and activate each other.

And the IL -2 receptor is a famous example of the complexity here.

Right.

It uses two different JAKES, JAK1 and JAK3, and it has three different chains.

One of them, the gamma chain, is actually shared by the receptors for a bunch of other interleukins.

It's so important that if you have a defect in that gamma chain gene, you get severe combined immunodeficiency, or SCID.

Once the JAKO is active, it phosphorylates the receptor tail, creating docking sites.

And this leads us right to the transcription factors of this pathway, the STAT proteins.

STAT stands for signal transducers and activators of transcription.

So a STAT protein has an SH2 domain.

It comes and docks onto a phosphotyrosine on the receptor, which positions it right next to the active JAK.

The JAKE then phosphorylates the STAT itself.

It does.

It phosphorylates a key tyrosine at the C -terminus of the STAT, and that's the activation signal.

The phosphorylated STAT then lets go of the receptor and finds another phosphorylated STAT.

They dimerize through a really cool reciprocal interaction, where the SH2 domain of one binds the phosphotyrosine of the other.

This dimerization unmasks their NLS, and the whole dimer zips off to the nucleus to turn on genes.

And again, the specific outcome depends on the cell type.

Completely.

The same activated STAT5 protein can turn on milk protein genes in a mammary cell, but it will turn on anti -apoptotic genes in a red blood cell progenitor.

Context is everything.

How do you shut this down?

It seems so direct and fast.

Two levels of feedback, again.

Short -term, there's a phosphatase called SHP1.

It has SH2 domains, so it docks onto the receptor, and that activates its phosphatase domain, which then dephosphorylates and inactivates the JAKinase.

And the long -term break.

That's mediated by the SOCS protein suppressors of cytokine signaling.

These are genes that are turned on by the STATs themselves.

This SOCS protein will bind to the activated receptor, but it also contains a module called a SOCS box.

And that brings in the destruction machinery.

It recruits an E3 ubiquitin ligase, which then targets both the JAKinase and the receptor for destruction by the proteasome.

It's a permanent shutdown.

Let's move to a pathway that uses a completely different type of kinase.

The TGF -beta family, which uses serine enthroning tenases.

The TGF -beta family is huge.

It regulates all sorts of developmental processes, but in most normal cells, its primary role is actually to inhibit cell proliferation.

It's a stop signal.

And losing that stop signal is a really common early step in cancer.

What's really fascinating about TGF -beta is how it's stored in this latent, inactive state in the extracellular matrix.

It is.

It's synthesized and secreted, but it's held captive, non -covalently attached to a protomane, and that whole complex is tethered to the matrix.

So how do you activate it?

Sounds like you need to physically release it.

You do.

It requires mechanical force.

It's an amazing mechanism.

A migrating cell, for instance, uses its integrins to pull on the matrix.

That pulling physically stretches the latent complex, like a ripcord, and that releases the active TGF -beta dimer.

So tissue tension can directly trigger a signaling pathway.

It can.

Once it's free, TGF -beta binds to its receptors, which are serine enthroning kinases.

The receptor is a complex of Ri and Ri.

Right.

TGF -beta binds to the Ri receptor, which is constitutively active.

That complex then recruits the Ri receptor.

Ri phosphorylates Ri, and that activates Ri's kinase activity.

And the downstream targets of Ri are the SMAD proteins.

Correct.

The active Ri kinase phosphorylates a specific type of SMAD called an R -SMAD.

What does that phosphorylation do?

It causes a conformational change that unmasks the NLS.

Then two of these phosphorylated R -SMADs team up with a co -SMAD SMAD4 to form a trimer.

And this trimeric complex is what goes into the nucleus.

And once it's in there, it works with other master transcription factors to regulate genes.

Exactly.

The final output, whether it's turning on cell cycle inhibitors or making matrix proteins, depends entirely on which other transcription factors are present in that particular cell.

And the negative feedback here.

A couple of mechanisms.

Proteins like SCI and SPROWN can bind to the SMAD complex and block it.

They also recruit histone -dase ethylases to shut down the chromatin.

And then there are inhibitory SMADs, I -SMADs, that can physically block the receptor.

Okay, we've covered a lot of phosphorylation.

Let's shift gears to a group of pathways that rely on something much more permanent.

Destruction.

Site -specific protein cleavage.

Yes.

These pathways are often irreversible, locking a cell into a new fate.

Starting with the Notch Delta pathway.

This is fundamental for cell fate decisions between two adjacent cells.

One cell, the signaling cell, has the ligand, delta.

The responding cell has the receptor, notch.

And the signal is transmitted by physical force.

It is.

Delta on one cell binds to notch on the other.

Then the signaling cell actually pulls on it through endocytosis.

That stretching exposes a cleavage site on notch for a protease called Adam -10.

That's the first cut.

Then there's the second, more unusual cut.

Yes.

A complex called gamma -secretase, which has the protease present in one,

makes a second cut within the plasma membrane itself.

That's a very tricky environment to do chemistry in.

And that second cut releases the active part of notch.

It releases the notch cytosolic segment, which is the transcription factor.

It goes straight to the nucleus, finds its DNA binding partner, and immediately changes gene expression.

We should note that these Adam proteases are general purpose releasers of signals.

That's a great point.

A lot of growth factors, like EGF, are made as transmembrane precursors.

And Adam proteases are what cleave them to release the soluble active signal.

Let's move to pathways that use the proteasome as a core signaling tool, starting with Wnt signaling.

Wnt is critical for development.

And the Wnt ligand is unique.

It's modified with a lipid palmitoleic acid, which helps it form gradients.

It binds to two receptors, Frizzled and LRP.

In the Wnt -RF state, the key transcription factor, beta -catenin, is constantly being destroyed.

It is.

It's held in this big beta -catenin destruction complex.

Crenases in this complex, Ck1 and Gsk3, are constantly phosphorylating it.

And that's the death tag.

That phosphorylation is the death tag.

It marks beta -catenin for ubiquitination and immediate degradation by the proteasome.

So in the OFF state, beta -catenin levels are basically zero.

So when the Wnt signal comes in, it has to shut down that destruction complex.

Worn binding to its receptors causes the whole destruction complex to fall apart.

So beta -catenin is no longer phosphorylated, it's no longer destroyed, and its levels rapidly build up in the cell.

And that free beta -catenin rushes into the nucleus.

It does.

It kicks a repressor off of the transcription factor, TCF, and together they turn on white target genes.

And misregulation here is a huge driver of cancer.

Over 90 % of colon cancers have a hyperactive white pathway.

And this brings us back to the planarian, the white gradient.

It does.

Wnt says, make a tail.

But at the head end of the worm, there's an inhibitor called notum that clips off that lipid anchor from white.

No lipid, no signal.

That's how it ensures a head grows at one end and a tail at the other.

Let's look at a similar pathway, hedgehog, which also uses the proteasome but in a totally different way.

Hedgehog is essential for patterning all sorts of things, like the neural tube and our limbs.

It also has a lipid -modified ligand.

The receptors are patched and smoothened.

And the hedgehog OFF state was happening.

In the OFF state, patched inhibits smoothened.

The transcription factor, called sciA or CLE, is held in a big complex.

There, it gets phosphorylated and then partially cleaved by the proteasome.

Partially cleaved.

Right.

It doesn't destroy the whole thing.

It just clips off the end, which generates a shorter fragment that acts as a transcriptional repressor.

So the default state is active repression of hedgehog genes.

So the hedgehog signal has to stop that cleavage from happening.

Exactly.

Hedgehog binds to patched, which stops patched from inhibiting smoothened.

Active smoothened then causes the big complex to fall apart.

So CIGLA is no longer cleaved.

The full -length protein is now stable.

And it acts as a transcriptional activator, going to the nucleus to turn on the genes.

And in vertebrates, this whole process is spatially organized in the primary cilium.

It is.

Which adds this whole other layer of regulation and connects it to a lot of developmental diseases called ciliopathies.

Our final mechanism is NF -kappa -B signaling.

This uses the opposite strategy again.

Destroy an inhibitor to release an activator.

NF -kappa -B is the master regulator of the immune system.

It gets turned on really fast in response to infection or inflammation.

And in the resting state, what's holding it back?

The NF -kappa -B protein dimer is held inactive in the cytosol because it's bound to an inhibitor protein called I -kappa -B alpha.

And I -kappa -B alpha's job is to physically cover up NF -kappa -B's nuclear localization signal.

So to activate the pathway, you have to destroy I -kappa -B alpha.

All the different activating signals converge on one kinase complex, the IKK complex.

IKK gets activated and it phosphorylates I -kappa -B alpha.

That phosphorylation is the signal for an E3 ligase to come in and ubiquitinate it.

And then it's off to the proteasome.

Immediate degradation by the proteasome.

I -kappa -B alpha is gone, NF -kappa -B's NLS is now exposed, and it rushes into the nucleus.

To launch a full -scale immune and inflammatory response.

It turns on over 150 genes.

Cytokines, chemokines, anti -apoptotic proteins, everything you need to fight an infection.

And the break on this one.

It's beautifully simple.

One of the genes that NF -kappa -B turns on is the gene for its own inhibitor, I -kappa -B alpha.

So it makes more of its own leash.

It makes more of its own leash.

The new I -kappa -B alpha goes into the nucleus, grabs NF -kappa -B, and drags it back out to the cytosol, shutting the signal off.

That brings us to the close of this incredibly detailed deep dive.

We've gone through seven major signaling architectures that all convert some fleeting external signal into a lasting genetic change.

We have.

And we've seen this remarkable diversity of strategies, all built on a conserved toolkit of binding domains, SH2, SH3, PH domains, that organize everything at the membrane.

We saw activation by phosphorylation with RTKs and stats.

We saw stabilizing and activated with Wnt.

Regulated proteolysis with Notch and Hedgehog.

And destroying an inhibitor with NF -kappa -B.

But the crucial takeaway is that the final decision the cell makes is never just about the signal.

It's about how that signal is integrated with the cell's internal context, its epigenetic state, and the other master transcription factors that define its identity.

Absolutely.

No pathway works in a vacuum.

And that integration leads us to our final provocative thought for you.

We saw that multiple pathways, NF -kappa -B, PKB, MAP -kannes, they all turn on anti -epoptotic pro -survival genes.

At the same time, tumor suppressors like PTN and TGF -beta signaling are trying to slam on the brakes.

There's this constant tension.

Exactly.

So how do cancer cells manage to so perfectly select and sustain only the activating mutations that help them survive, while at the same time disabling the natural checks and balances, the DUSPs, the SOCS proteins, that evolved to stop them?

What is the subtle genetic or epigenetic change that's required to tip, that evolve regulatory balance, maybe irrevocably toward malignancy?

That is a biological puzzle worth pondering.